Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 326

1.

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.

N Engl J Med. 2003 Feb 13;348(7):601-8.

3.

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.

Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P.

Gastroenterology. 2003 Apr;124(4):917-24.

PMID:
12671888
4.

Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.

Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.

Dig Liver Dis. 2004 May;36(5):342-7.

PMID:
15191204
5.

Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.

Kinney T, Rawlins M, Kozarek R, France R, Patterson D.

Am J Gastroenterol. 2003 Mar;98(3):608-12.

PMID:
12650795
6.
7.

Infliximab maintenance therapy for fistulizing Crohn's disease.

Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ.

N Engl J Med. 2004 Feb 26;350(9):876-85.

8.

Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.

Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG.

Am J Gastroenterol. 2000 Nov;95(11):3189-94.

PMID:
11095340
9.

Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.

Keating GM, Perry CM.

BioDrugs. 2002;16(2):111-48. Review.

PMID:
11985485
10.
11.

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ.

Gastroenterology. 1999 Oct;117(4):761-9.

PMID:
10500056
12.
13.

Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings.

Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, Hobara R, Nakano H, Okamura S, Matsueda K, Kashida H, Makiyama K, Hiwatashi N, Kashiwagi K, Hibi T.

J Gastroenterol Hepatol. 2001 Jul;16(7):763-9.

PMID:
11446884
14.

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.

Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P.

Gut. 2007 Sep;56(9):1226-31. Epub 2007 Jan 17.

15.

[Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea].

Choi KD, Song HJ, Kim JS, Jung HC, Song IS.

Korean J Gastroenterol. 2005 Jul;46(1):48-55. Korean.

16.

Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.

Lamireau T, Cézard JP, Dabadie A, Goulet O, Lachaux A, Turck D, Maurage C, Morali A, Sokal E, Belli D, Stoller J, Cadranel S, Ginies JL, Viola S, Huet F, Languepin J, Lenaerts C, Bury F, Sarles J; French-Speaking Group for Pediatric Gastroenterology Nutrition.

Inflamm Bowel Dis. 2004 Nov;10(6):745-50.

PMID:
15626892
17.

Infliximab in the surgical management of complex fistulating anal Crohn's disease.

Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D.

Colorectal Dis. 2005 Mar;7(2):164-8.

PMID:
15720356
18.

The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.

Moss AC, Fernandez-Becker N, Jo Kim K, Cury D, Cheifetz AS.

Aliment Pharmacol Ther. 2008 Jul;28(2):221-7. doi: 10.1111/j.1365-2036.2008.03734.x. Epub 2008 May 12.

19.

Use of infliximab in the treatment of Crohn's disease in children and adolescents.

Hyams JS, Markowitz J, Wyllie R.

J Pediatr. 2000 Aug;137(2):192-6.

PMID:
10931411
20.

Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study.

Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, Joossens S, Bossuyt X, Rutgeerts P.

Gastroenterology. 2003 Jul;125(1):32-9.

PMID:
12851868
Items per page

Supplemental Content

Write to the Help Desk